|
Aurobindo Pharma in the News |
|
Monday, 18 June 2007 |
|
* With strong process chemistry skills, Aurobindo has graduated from being a mere API player to a strong formulation player in the global markets.
* Aurobindo boasts of a product pipeline of 110 DMFs and 82 ANDA filings for the US market. With major approvals having come through in FY2007, we expect incremental revenue of Rs100 crore from the US generic business.
* Being a strong player in the anti-HIV market, Aurobindo has secured several new product approvals for its ARV products. We expect Aurobindo's ARV formulation revenues to reach $99 million and $128.7 million in FY08 and FY09 respectively.
* The above initiatives are expected to translate into revenue and earnings CAGR of 24.3% and 70% respectively over FY2007-09E, yielding EPS of Rs57.1 in FY2009E. At the CMP of Rs698, the stock trades attractively at 15.2x FY2008E and 12.2x FY2009E earning estimates.
Bear Stearns (BSC). Oddest buyout DealDear Reader, I have to tell you that I was absolutely shocked on Sunday, March 16, when I heard the news that J.P. Morgan (JPM) was buying Bear Stearns (BSC). It wasn’t the fact that JPM...
+ Full Story | Investing Ideas for 2008By Charles Delvalle All signs point to a big slowdown this year. And if you don’t change the way you invest, you’ll lose a lot of money. There are two great ways to make money...
+ Full Story |
- We endeavor to decipher analysis of this Teaser/News Letter to distinguish
the thoughts of Authors/Editors.
- Please post your Review/Comments, your rating helps other users gauge the value of an article ...
-
-
|
Market Watch 
